06618 JD HEALTH
- 27.150
- -0.350-1.27%
JD HEALTH News
2023 年度報告
JD.com's 1Q Revenue Likely Supported by Low-Price Strategy, Better User Experience -- Market Talk
JD.com's low-price strategy and user experience enhancement likely sustained its gross merchandise value growth momentum and supported 1Q revenue growth, Daiwa analysts John Choi and Robin Leung say in a research note.
[Broker Focus] Tianfeng Securities maintains JD Health (06618) “buy” rating and is optimistic about the continued penetration of active users and the guarantee of omni-channel supply chain capabilities
Jinwu Financial News | According to Tianfeng Securities Research, JD Health (06618) achieved operating revenue of 53.5 billion yuan in 2023, an increase of 14.5% over 46.7 billion yuan in the same period last year; by business, the company's own product revenue in 2023 was 45.65 billion yuan, up 13.1% year on year; service revenue was 7.88 billion yuan, up 23.7% year on year. The company's gross margin increased by 1.0 pct to 22.2%, mainly due to changes in the product portfolio; annual profit was 2.14 billion yuan, up 459.2% year on year, and adjusted non-IFRS net profit reached 4.14 billion yuan, compared with 2
Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy
05:00 AM EDT, 03/22/2024 (MT Newswires) -- Nomura Adjusts JD Health's Price Target to HK$44 to HK$37, Keeps at Buy Price (HKD): $28.05, Change: $-4.05, Percent Change: -12.62%
JD Health's 2023 Profit Soars Almost Sixfold to Over 2 Billion Yuan
JD Health International (HKG:6618) recorded a nearly sixfold surge in attributable profit for the year ended Dec. 31, 2023, to 2.14 billion yuan from 380.1 million yuan in 2022, a Wednesday filing on
[Hong Kong Stock Connect] JD Health (06618)'s profit of RMB 2,142 billion last year increased 463.49% year over year
Jinwu Financial News | JD Health (06618) announced that in 2023, the company's shareholders should account for profit of RMB 2,142 billion, an increase of 463.49% over the previous year; basic profit per share was 0.69 yuan. During the period, the company's revenue increased 14.5% from RMB 46.7 billion in 2022 to RMB 53.5 billion in 2023. In detail, the increase in the company's total revenue is mainly due to a 13.1% increase in product revenue from sales of pharmaceuticals and health products from RMB 40.4 billion in 2022 to RMB 45.7 billion in 2023. The main drivers for the growth of commodity revenue are
JD Health: 2023 Revenue Growth Driven by Higher Pharmaceutical and Healthcare Product Sales >6618.HK
JD Health: 2023 Revenue Growth Driven by Higher Pharmaceutical and Healthcare Product Sales >6618.HK
JD Health 2023 Rev CNY53.53B Vs. CNY46.74B >6618.HK
JD Health 2023 Rev CNY53.53B Vs. CNY46.74B >6618.HK
JD Health (06618) announced annual results, profit attributable to shareholders of 2.42 billion yuan, a sharp increase of 463.49% year-on-year, and the average number of online consultations throughout the year has exceeded 450,000
JD Health (06618) announced its annual results for the year ended December 31, 2023. The group will take...
JD HEALTH-R: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
JD HEALTH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
In 2024, what areas will JD Health focus on?
Sina Technology News On the afternoon of March 12, JD Health CEO Jin Enlin said at the 4th JD Health Partners Conference that in 2023, JD Health will further strengthen infrastructure construction, promote business innovation and experience upgrading, and continue to consolidate the “first entrance to online health consumption” advantage.
JD Health (06618.HK) plans to hold a board meeting on March 20 to consider and approve annual results
Gelonghui, March 8, 丨 JD Health (06618.HK) announced that the company will hold a board meeting on March 20, 2024 (Wednesday) to approve (among other things) the results of the company and its subsidiaries for the year ended 31 December 2023 and consider the proposed payment of a final dividend (if any). The Company's management will hold a conference call on March 21, 2024 (Thursday) at 9:30 a.m. (Beijing/Hong Kong time) to discuss the financial results of the Company and its subsidiaries for the year ended 31 December 2023.
JD HEALTH-R: DATE OF BOARD MEETING
JD HEALTH: DATE OF BOARD MEETING
CICC: Maintaining JD Health's “Outperforming Industry” Rating Target Price of HK$41.2
CICC released a research report stating that maintaining the JD Health (06618) “outperforming the industry” rating, considering the frequent influenza situation in various regions starting in 4Q23, it is expected to increase the 2023 profit forecast by 2% to 1.8 billion yuan. The 2024/2025 profit forecast remains unchanged, with a target price of HK$41.2. The bank expects the company's revenue side to achieve a year-on-year growth rate of about 15% in 2023. CICC's main views are as follows: It is expected that overall growth may be steady in 2023. 1-3Q23 achieved revenue of 38.696 billion yuan (+25
CICC: Maintaining JD Health's (06618) “Outperform the Industry” rating target price of HK$41.2
CICC expects JD Health (06618) to achieve a year-on-year growth rate of about 15% on the revenue side in 2023.
Hong Kong Stock Announcement Nuggets | Privatization opens, the premium is 34.11%, see what is the opening discount?
Whether privatization is reasonable depends on whether the price is in line with the valuation level. With the current price premium of 34.11%, privatization of almost 1.05 pb (Pb caliber at the end of 2023) is OK.
JD Health (06618) issues 500,000 shares under the share award program
According to the Zhitong Finance App, JD Health (06618) announced that the company will issue 500,000 new shares on February 21, 2024 in accordance with the adoption of the initial public offering after-sales share incentive plan on November 23, 2020.
JD Health [06618] now reports HK$27.15, a decrease of 5.07%
As of 09:52, JD Health [06618] reported HK$27.15, down 1.45 HK$5.7% from yesterday's closing price of HK$28.6, with a turnover of HK$11.9838 million. Today's high price was HK$28.3 and the lowest price was HK$27.15. Based on yesterday's closing price, the 10-day average price was HK$27.22, and the 50-day average price was HK$33.23. The current price-earnings ratio was 208.45 times, and the 14-day strength and weakness index was 50.21.
Analysis
Price Target
No Data
